AI-CVD vs ClearRead CT

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 75/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

AI-CVD

by HeartLung AI

ClearRead CT

by Riverain Technologies

AI Verdict

AI-CVD focuses on opportunistic screening for a broad range of cardiovascular and multisystem diseases, offering detailed cardiac volumetry and various calcification analyses. ClearRead CT, while also providing coronary artery calcification scoring, specializes in advanced pulmonary nodule detection, characterization, and tracking with vessel suppression technology. Therefore, AI-CVD is better suited for comprehensive cardiovascular risk assessment from existing CTs, while ClearRead CT excels in enhancing lung cancer screening and diagnosis.

Choose AI-CVD if…

Choose AI-CVD if your primary goal is to opportunistically screen for a wide range of cardiovascular and multisystem diseases using existing CT scans, without requiring additional imaging or workflow changes. This platform is ideal for maximizing the diagnostic value of previously acquired chest and abdominal CTs to detect hidden risks like coronary artery calcium, aortic valve calcification, and abnormal cardiac chamber volumes.

View AI-CVD →

Choose ClearRead CT if…

Choose ClearRead CT if your focus is on significantly improving the accuracy and efficiency of pulmonary nodule detection, characterization, and tracking in CT scans. This tool is particularly beneficial for lung cancer screening programs and follow-up, offering advanced vessel suppression technology and automated nodule measurement and comparison features to streamline radiologist workflow and reduce missed actionable findings.

View ClearRead CT →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	AI-CVD	ClearRead CT
Pricing	Unknown	Contact for pricing
Deployment	Unknown	On-premise (stand-alone server, virtual machine) and Cloud
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

ClearRead CT

ClearRead CT directly enhances the radiologist's workflow by reducing reading times and seamlessly integrating into PACS for improved nodule detection, as evidenced by user feedback and studies. While AI-CVD aims for no workflow disruption, ClearRead CT actively improves the efficiency of the primary reading task.

Clinical Value

Tie

Both tools offer significant and validated clinical value. AI-CVD provides broad, opportunistic, multisystem screening for a wide array of conditions, leveraging existing scans to detect hidden risks often missed by human eyes. ClearRead CT offers a highly quantified improvement in pulmonary nodule detection accuracy and reading efficiency, directly impacting lung cancer screening and diagnosis.

Pricing & Value

Tie

Both tools offer significant, albeit unquantified, economic value through improved efficiency, diagnostic accuracy, or early disease detection. ClearRead CT provides direct operational savings through reduced reading times and improved accuracy. AI-CVD's CMS reimbursement for a core module and its broad opportunistic screening capabilities suggest strong value in preventative care and long-term cost reduction.

Enterprise Readiness

ClearRead CT

ClearRead CT offers superior enterprise readiness due to its flexible deployment options (on-premise and cloud), explicit seamless PACS integration, vendor-neutral processing, and a demonstrated track record of adoption in large healthcare systems, including VA medical centers.

Innovation

AI-CVD

AI-CVD demonstrates greater innovation through its comprehensive, opportunistic, multisystem screening approach that transforms existing CT scans into a broad preventative health platform, identifying a wide array of hidden health risks without additional procedures. This represents a more paradigm-shifting application of AI compared to ClearRead CT's specific, albeit advanced, vessel suppression technology.

Support & Docs

ClearRead CT

Although specific details are scarce for both, ClearRead CT's partnership with Philips and the presence of a 'Support' section on Riverain's website suggest a more developed and accessible support and documentation infrastructure compared to AI-CVD, for which no such explicit information was found.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	AI-CVD	ClearRead CT
Name	AI-CVD	ClearRead CT
Company	HeartLung Corporation	RIVERAIN TECHNOLOGIES
Primary Focus	AI-powered quantitative imaging platform for opportunistic screening for cardiovascular and multisystem diseases using existing CT scans.	AI suite for cardiothoracic health, enhancing pulmonary nodule detection and coronary artery calcification analysis in CT scans.
Coronary Artery Calcium (CAC) Scoring	Yes	Yes (ungated, non-contrast CTs)
Pulmonary Nodule Detection	Not specified	Yes (solid, part-solid, ground glass)
Cardiac Chamber Volumetry	Yes (Left Atrium, Left Ventricle, Right Atrium, Right Ventricle)	Not specified
Vessel Suppression	Not specified	Yes (Patented Vessel Suppression (Clear Visual Intelligence))
Opportunistic Screening	Yes (from existing chest and abdominal CT scans)	Not specified